Glaukos Co. (NYSE:GKOS) CFO Sells $46,714.98 in Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 442 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $105.69, for a total value of $46,714.98. Following the sale, the chief financial officer now owns 52,090 shares of the company’s stock, valued at approximately $5,505,392.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Glaukos Stock Performance

NYSE:GKOS opened at $106.91 on Thursday. The company has a market cap of $5.38 billion, a price-to-earnings ratio of -37.12 and a beta of 1.08. The stock’s 50 day simple moving average is $94.28 and its two-hundred day simple moving average is $83.79. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.68. Glaukos Co. has a 1 year low of $54.38 and a 1 year high of $110.73.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The company had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The company’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.59) earnings per share. As a group, equities analysts anticipate that Glaukos Co. will post -2.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on GKOS. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 price target on shares of Glaukos in a research report on Wednesday, April 3rd. BTIG Research increased their target price on shares of Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. upped their price target on shares of Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Jefferies Financial Group upgraded shares of Glaukos from a “hold” rating to a “buy” rating and raised their price objective for the company from $84.00 to $125.00 in a research report on Monday. Finally, Mizuho upped their target price on shares of Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.64.

Institutional Investors Weigh In On Glaukos

Several institutional investors have recently made changes to their positions in the company. Brown Capital Management LLC increased its stake in Glaukos by 3.4% in the 4th quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock worth $214,448,000 after buying an additional 89,420 shares during the period. Fred Alger Management LLC lifted its stake in shares of Glaukos by 9.2% during the 3rd quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier’s stock worth $133,997,000 after purchasing an additional 150,102 shares during the last quarter. Invesco Ltd. raised its stake in shares of Glaukos by 45.5% during the 3rd quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier’s stock worth $109,115,000 after acquiring an additional 453,756 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Glaukos by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock worth $73,412,000 after purchasing an additional 31,213 shares during the last quarter. Finally, Primecap Management Co. CA increased its holdings in shares of Glaukos by 23.7% during the fourth quarter. Primecap Management Co. CA now owns 790,035 shares of the medical instruments supplier’s stock valued at $62,800,000 after acquiring an additional 151,415 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.